Advertisement

Topics

AZ withdraws Brilinta batch for containing the wrong drug after packaging mix-up

04:51 EDT 6 Jun 2017 | Pharmafile

The United Arab Emirates Ministry of Health and Prevention has called for the withdrawal of a batch of AstraZeneca’s cardiovascular drug Brilinta (ticagrelor) 90mg with immediate effect, after it was discovered that, because of a packaging error, the supposed treatment instead contained Zurampic (lesinurad) 200mg, a gout therapy also manufactured by the company.

read more

Original Article: AZ withdraws Brilinta batch for containing the wrong drug after packaging mix-up

NEXT ARTICLE

More From BioPortfolio on "AZ withdraws Brilinta batch for containing the wrong drug after packaging mix-up"

Quick Search
Advertisement
 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...